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CLINICAL TRIALS
Crossover Trials with a Binary Response: A
Powerful Method Despite the
Carryover Effect
Ton IM . CleoDhas. MD. PhD, FICA, FACA, and Henk J. J. van Lier, MSc, PhD
The two-period crossover trial has the ev iden t advantage  that, by  use o f  w ith in -pa tien t  
comparisons, the usual large between-patient variability  is not used as a m easure  to co m ­
p a re  treatments. A  prerequisite, however, is that the order o f  the trea tm en ts  does not su b ­
s tan tia lly  in fluence the outcom e of the trea tm en t , Crossover studies  with a b in a ry  r e ­
sponse fsuch as yes /no  or present/absent) ,  a lthough widely used for initial sc reen in g  of 
new com pounds, have not previously  been  studied for such  o rder  effects. This  s tu d y  uses  
a m a them atica l m odel based on s tan d a rd  statistical tests to s tu d y  to what e x ten t  such  
order effects , here identical to carryover effects, m ay  reduce the pow er of delecting  a trea t­
m en t effect. It is concluded  that, despite large carryover effects, the crossover s tu d y  w ith  a 
b inary  response rem a in s  a powerful m ethod and that testing for ca rryover  effects m a k es  
sense only  i f  the null hypo thesis  o f  no trea tm ent effect cannot be rejected.
T he crossover design is widely used in clinical re­
search, especially in instances where a limited 
number of patients is available for a study, The main 
advantage of within-patient comparisons in compar­
ison to between-patient comparisons is that be- 
tween-subject variability is not used in the compari­
sons. A prerequisite, however, for this type of trial is 
that the order of the treatments does not influence 
the outcome of the treatment. If the effect of the 
treatment administered in the first period carries 
over into the second period, then it may influence 
the measured response in the second period. This es­
sentially means that only symptomatic treatments 
qualify for crossover comparisons and curative treat­
ments do not.
Symptomatic treatments frequently have small 
curative effects, however, such as wound healing by 
vasodilators or, more recently, cardiac remodeling 
by afterload reduction. The treatment group that is 
treated with the effective compound first and with
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the less effective compound or placebo second is fre­
quently biased by carryover effect from the first pe­
riod to the second, whereas the alternative group 
that is treated in the reverse order is not so.1 For ex­
ample, of 73 reports of crossover trials published in 
1989-1990,2 only 6 reported the data of the separate 
periods, In 5 of them  (83%) this very type of carryover 
effect was demonstrable. Such a m echanism  may 
cause a severe underestim ation of the treatm ent re­
sults,2 and this possibility should, therefore, be as­
sessed in the analysis,
Most of the reports on the subject of order effects 
so far have addressed crossover studies with a quan­
titative rather than binary response/1 1(1 Although 
Hills and Armitage11 mentioned the tests of Gart12 
and Prescott™ for crossover trials with a binary re­
sponse in their overview of methods in crossover 
clinical trials and Fidlcr1*1 presented a model, little 
attention has been paid to those kinds of trials. A bi­
nary response is different from a quantitative re­
sponse in that it generally does not answ er w hat ex­
actly can be expected in an individual. Rather it ad­
dresses w hether or not a particular result has a 
predictive value, which of two treatm ents is better, 
or w hether there is a treatment effect in the data. 
One might contend, therefore, that some undervalu­
ation of a difference in binary data is not that impor­
tant as long as it does not cause a type II error by in-
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TABLE I
Example of a Crossover Design with a Binary
Response
Period 1 Period 2
Probability of Probability of
Treatment Treatment
Group Treatment Success Treatment Success
1 A pA B Pb
II B pB A P£
* If in Group II treatment B has a carryover effect on the outcome of treatment 
A, pA changes to pc. If Pb ~ Po carryover effect is maximal.
dicating no difference w ere  there  is one. The m ain  
purpose of our analysis was to exam ine w hether  in  
crossover trials with a b inary  response a significant 
carryover effect does leave enough power in the data 
to dem onstrate  a trea tm en t effect.
ASSESSM ENT OF C A R R Y O V ER  AND 
T R E A T M E N T  EFFECT
In a crossover trial w ith  two treatm ents  and two 
treatm ent periods, patients are assigned in a random ­
ized fashion to two sym m etric  groups that are given 
treatments A and B in a different order (Table I). If 
groups are sym m etric  and the results are not influ­
enced by the order of the treatments, the probabili­
ties of trea tm ent success in  groups I and 2 should be 
virtually the same in each period for each treatment; 
pA being the probability of trea tm en t success from 
treatment A and pu the probability of treatm ent suc­
cess from treatm ent B (Table I), Results from the 
group that is treated with the less effective trea tm ent 
or placebo after the more effective are in danger of 
being biased by carryover effect from the first period 
to the second.
Suppose trea tm ent A is far less effective than t re a t ­
ment B (Table I). Then, if in group 2 treatm ent B has 
a carryover effect on the outcom e of treatm ent A, the 
probability of trea tm ent success changes from pB to 
pc. To detect a carryover effect we compare the o u t­
comes of trea tm en t A in group 1 to the outcomes of 
treatm ent A in group 2; p A versus pc> an unpaired 
comparison. The am oun t of carryover effect in group
2 is considered to be the difference betw een pc and 
pA. Carryover effect in group 1 (ineffective trea tm ent 
period before effective treatment) is assumed to be 
negligible. Time effect is assum ed to be negligible as 
well, because we study stable disease only.
It thus seems that ne ithe r  a test for carryover effect
in group 1 nor a tes t for t im e  effects needs  to be  in ­
c luded  in o u r  assessm ent. T re a tm e n t  effect is as­
sessed by tak ing  the tw o groups together, after w h ich  
all outcom es of t r e a tm e n t  A are  com pared  w ith  those 
of trea tm en t B in a p a ired  com parison . T he  a ssu m p ­
tion that carryover effect in  group 1 is negligible im- 
pli es tha t  th e  test for ca r ry o v er  effect uses only half  
of the  available da ta  and  m igh t there fo re  be expected  
to be less sensitive. S ensit iv ity  no t only  depends on 
sample size, how ever, b u t  also on the size of differ­
ences and  th e i r  variances.
S T A T IS T IC A L  M O D E L F O R  T E S T IN G  
T R E A T M E N T  A N D  C A R R Y O V E R  E FFE C T S
We assum e a u n id irec t io n a l  assessm ent w h ere  p is 
b e tw een  0.0 (no m ore  sym ptom s) a n d  1.0 (100% of 
patien ts  rem a in  sy m p to m atic  despite  treatm ent). 
W hen  carryover effect is in th e  data, p A for group 2 
becom es pc (Table I). T he  difference b e tw e e n  pc and  
pA is considered to be the  a m o u n t  of carryover effect 
in  the data. F isher’s exac t  tes t is used  to d e te rm in e  
w h e th e r  pc is significantly d ifferent from pA. Using 
th e  program of Bavry,15 the  va lues  for pc tha t sh ou ld  
yield a significant ca r ry o v er  effect in  80% of the trials 
(i.e., pow er = 80%) are  d e te rm in ed .  A n u m b e r  of p a ­
tients b e tw een  10 a n d  25 is chosen  for both groups, 
because m an y  crossover tria ls  have 20 to 50 patients. 
T he  values for pc a re  th e n  used  to d e te rm in e  
w h e th e r  enough p o w er  is left in  th e  data  to d e m o n ­
strate a significant t r e a tm e n t  effect in crossover trials 
w ith  significant ca rryover  effect and  a b inary  re ­
sponse.
TABLE II
Power to Demonstrate a Treatment Effect in Spite of
the Presence of a Significant Carryover Effect
Total No. of Patients




0.40 96 (0.02) 97 (0.05) 96 (0.08)
0.50 97 (0.06) 96 (0.11) 96 (0.14)
0.60 97(0.04) 98 (0.11) 96 (0.18) 95 (0.23)
0.70 96 (0.11) 97 (0.20) 97 (0.26) 94 (0.33)
0.80 96 (0.20) 97 (0.30) 97 (0.37) 96 (0.43)
0.90 96(0.31) 97 (0.43) 96 (0.47) 96 (0.52)
Values are power (%) of McNemar test for treatment effect (a = 0.05, p = 0) 
[pc value just yielding a significant test for carryover effect (a = 0,05, power — 
80%)].
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TABLE III
Power (%) to Demonstrate a Treatment Effect in
Spite of the Presence of a Significant
Carryover Effect
Total No. of Patients
P 2 X  10 2 x  15 2 X 2 0 2 x 2 5
ori = 0.05 -0 .2 0 89 94 96 95
dz = 0.05 -0 .1 0 92 96 97 97
0 96 96 96 94
0.10 98 97 98 99
0.20 98 98 99 99
«1 = 0.01 -0 .2 0 95 99 94 99
«2 = 0.01 -0 .1 0 97 100 99 99
0 99 99 99 99
0.10 100 100 100 100
0.20 100 100 100 100
«1 -  0.10 -0 .2 0 74 84 89 88
a  2 = 0.05 -0 .1 0 79 91 92 90
0 85 90 89 88
0.10 89 95 95 94
0.20 95 94 97 97
CXi = 0.05 -0 .2 0 75 87 90 90
«2 = 0.01 -0 .1 0 81 92 92 93
A 0 88 90 90 89
0.10 92 93 95 96
0.20 96 96 98 98
a 2, level of significance of test for carryover effect; a2, level of significance of 
test for treatment effect; p ,  level of correlation between treatments A and B.
To test the treatment effect, all data for treatment 
A are taken together and compared with data for 
treatment B. The power of this test depends not only 
on the probabilities pA and pB, but also on the corre­
lation between the treatment responses. This corre­
lation is expressed as p  =  pA/B ~~ P a ,  where pA/B is the 
probability of treatment success with treatment A, 
given that treatment B was successful. When p =  0, 
treatments A and B act independently. When pn 
equals pc> this would mean that the carryover effect 
in group 2 is not only significant but also maximal, 
given the amount of treatment effect. Considering 
this situation of maximal carryover effect, we calcu­
late the power of detecting treatment effects. The 
power of the McNemar test, with pB being equal to pc 
and various values for p ,  was calculated according to 
Bavry.15
RESULTS
Calculation of pc Values Yielding a Significant 
Result for Carryover Effect
For various numbers of patients and various values 
of pA (the probability of success with treatment A in
period 1; Table I), the pc values (the probability of 
success w ith  treatm ent A in period 2) are calculated 
so that a power of 80% will yield a significant test for 
carryover effect (pA versus Pc; a  = 0.05). Table II 
shows that carryover effects (difference between pA 
and pc) as large as 0.60, 0.50, 0.40, and  0.35 are re­
quired for a significant test. For a  -  0.01, these values 
are approximately 0.70, 0,60, 0.50, and  0.45. Using 
these pc values, we then  calculated the probability 
of detecting a treatm ent effect (i.e., pow er of testing 
treatment effect). We report m inim al values of power 
only, i.e., the situation w here p B = pc. W henever pB 
< pc, we would have an even better power for testing 
treatment effect.
Power of Paired Comparison for Treatment Effect
W hen the result of treatm ent B (pB) is taken equal to 
the maximal values of pc and trea tm ents  A and B act 
independently [p = 0), the probability or power of de­
tecting a treatm ent effect in the crossover situation 
when n is betw een 20 and 50 is always more than 
94% (Table II). Usually, however, trea tm ents  A and 
B do not act independently. With a negative correla­
tion between the two treatm ent modalities power is 
lost, and with a positive correlation it is augmented. 
Table III shows power values adjusted for different 
levels of p. With negative levels of p and  20 patients, 
the power for detecting a treatm ent difference is not 
less than 74%, w hich is approximately as large as 
that chosen for the test on carryover effect (80%). 
When more patients are adm itted  to the trial this 
value will be ~90% .
EXAMPLES
Suppose we have a negative crossover in which the 
probability of treatment success in group 2 pc (Table 
IV) may have changed from 0.8 into 0.2 due to carry­
over effect from the effective treatment B into the 
second period. Fisher’s exact test for demonstrating
TABLE IV
Example
Period 1 Period 2
Probability of Probability of
Treatment Treatment
Group Treatment Success Treatment Success
I (n = 10) A Pa — 0.8 B pB -  0-2
II (n = 10) B pa = 0.2 A pc = 0.2
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a carryover effect (pA versus pc) is calculated accord­
ing to
Point probability for carryover effect
10! 10! 10! 10!
“  .----= 0-011
2 0 ! 2 ! 8 ! 2 ! 8 !
Cum ulative tail probability = 0.011 + 0.003 H- 
0.007 = 0,021 and is thus significant at a level of a  = 
0 . 0 2 1 ,
If we perform  a similar unpa ired  analysis of the 
first period to dem onstra te  a trea tm ent effect, we 
likewise obtain a significant test at a level of a - 
0,021. Suppose carryover effect w ould  be smaller, 
P a  “  0.8, pB =  0.0, pc =  0.2. T hen  the test for 
trea tm ent effect w ould  yield an even better result:
Point probability for carryover effect
29! 8! 10! 10!
2 0 ! 2 ! 8 ! 1 0 ! 0 !
Cumulative tail probability = 0.004 -f 0.001 -f 
0.003 = 0.008.
Therefore, in crossovers with a binary response 
and a negative result, it does make sense to test for 
carryover effect by comparing the two periods with 
the less effective treatment modalities. If a significant 
test is demonstrated, we obviously will find a sig­
nificant difference at a similar or even lower level of 
significance when taking the first period for estimat­
ing the difference between treatment A and B. Thus, 
it would seem appropriate for our purpose to disre­
gard the data of the second period in this particular 
situation (although the second period might still pro­
vide interesting information).
DISCUSSION
The power of crossover studies is frequently reduced 
by carryover effect. This is particularly so when a 
group that is treated with an effective treatment first 
is then treated with an ineffective treatment or pla­
cebo second. In studies with a quantitative response, 
this very effect may cause severe underestimation of 
the treatment effect.1 Studies with a binary response 
are different from studies with a quantitative re­
sponse, however, in that they are mostly designed to 
determine whether a treatment has any effect rather 
than the magnitude of that effect, One might 
contend, therefore, that underestimation in such 
studies is not important as long as the null hypothesis 
of no treatment effect doesn’t have to be erroneously 
accepted. We demonstrate that in crossover trials
with a binary response and significant carryover 
effect, the power of testing the treatment effect re­
mains substantial. This would imply that routinely 
testing for carryover effects in such studies is not 
necessary as long as the result of the treatment com­
parison is positive. When a study is negative it does 
make sense, however, to test for carryover effect by 
comparing pA and pc (Table I).
When pA is significantly different from pc, we as­
sume that there is a carryover effect in group 2. In 
this situation, a parallel-group analysis of period 1 (pA 
versus pB) can effectively be used to demonstrate a 
treatment effect. This will provide a significant 
difference at a similar or even lower level of signifi­
cance than the test for carryover effect. This occurs 
because pB equals pc w hen  carryover effect is maxi­
mal. The difference between pB and pA will therefore 
be at least as large as the difference between pc and 
pA, and may be larger. Therefore, no further test for 
treatment effect seems to be required for our 
purposes, and it seems appropriate that the results of 
the second period be disregarded.
Considering that the influence of carryover effects 
in crossover trials with a binary response may not be 
a problem, we should shift our standards for choos­
ing this particular trial design and make use of its 
additional advantages more frequently. For exam­
ple, this design is particularly powerful for study of 
rapid relief of symptoms in chronic disease in which 
the long-term condition of the patient remains fairly 
stable.16 This is because between-subject variability 
is not a factor in a within-subject comparison. Also, 
we can make use of positive correlations between the 
treatment modalities tested, because the statistical 
power of testing treatm ent comparisons with a posi­
tive correlation can be largely enhanced by within- 
subject comparisons.37 Further, none of the patients 
in the trial has to be treated throughout the trial with 
a less adequate dose or placebo, which is why a cross­
over design usually raises fewer ethical considera­
tions than does a parallel-group design in which one 
group is treated with placebo or less adequate dosage 
throughout the trial. Also, there is the advantage that 
patients can express their own opinions about which 
treatment they prefer. This is particularly important 
with subjective variables such as pain scores. The 
crossover design also does not require a large study 
group, because within-subject comparison facilitates 
the recruitment procedure and reduces costs. Fi­
nally, a double-blind design cannot be effectively ex­
ecuted in self-controlled studies without some kind 
of crossover element.
We therefore conclude that crossover studies with 
a binary response and positive results do not have to 
be tested for carryover effects. If such studies have a
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negative result, how ever, testing for carryover effect 
does m ake  sense. If a carryover effect is dem on­
strated, the  t rea tm en t  results  should  be analyzed in 
the  form of a paralle l-group study using the data from 
the first period.
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